Current Rheumatology Reports

Who Would Have Predicted Multisystem Inflammatory Syndrome in Children?.  24. 2022

Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis.  21. 2019

Rituximab in ANCA-Associated Vasculitis.  19. 2017

Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.  18. 2016

Racial/Ethnic Disparity in Rates and Outcomes of Total Joint Arthroplasty.  18. 2016

Genetic Defects in Cytolysis in Macrophage Activation Syndrome.  16. 2014

Vaccinations for rheumatoid arthritis.  16. 2014

Infectious complications in juvenile idiopathic arthritis.  15. 2013

Racial and gender disparities among patients with gout.  15. 2013

Osteopenia: Debates and dilemmas.  15. 2013

What is the background incidence of malignancy in children with rheumatic disease?.  15. 2013

Managing macrophages in rheumatoid arthritis by reform or removal.  14:445-454. 2012

From fracture risk prediction to evaluating fracture patterns: Recent advances in the epidemiology of osteoporosis.  14:205-211. 2012

Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.  13:273-282. 2011

Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?.  12:342-347. 2010

Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: Cross-cultural issues.  12:237-249. 2010

Bone changes and fracture risk in individuals infected with HIV.  12:163-169. 2010

The societal burden of osteoporosis.  12:186-191. 2010

Uric acid and hypertension: Cause or effect?.  12:108-117. 2010

Quality of life and quality of care for patients with gout.  11:154-160. 2009

Tumor necrosis factor inhibitors and infection complications.  10:383-389. 2008

Update on pathogenic mechanisms of systemic necrotizing vasculitis.  10:430-435. 2008

Improving quality of care in osteoporosis: Opportunities and challenges.  10:123-130. 2008

The use of zoledronic acid for osteoporosis..  10:89-91. 2008

Therapeutic advances in calcium and vitamin D for osteoporosis..  10:90-91. 2008

Calcium and vitamin D: Skeletal and extraskeletal health.  10:110-117. 2008

Denosumab in postmenopausal women with low bone mineral density..  9:48. 2007

Ibandronate injections in postmenopausal women with osteoporosis..  9:47. 2007

New directions in osteoporosis therapy: Intravenous ibandronate and denosumab.  9:47-49. 2007

Not just calcium and vitamin D: Other nutritional considerations in osteoporosis.  9:85-92. 2007

Uveitis: Advances in understanding of pathogenesis and treatment.  8:260-266. 2006

Low-dose prednisolone in early rheumatoid arthritis.  8:48-49. 2006

The use of low-dose glucocorticoids for the treatment of early rheumatoid arthritis: What can we learn about bone effects of glucocorticoids from randomized controlled trials?.  8:47-48. 2006

Classification of the vasculitides: are they clinically useful?.  7:265-269. 2005

Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?.  7:242-249. 2005

Recent advances in the epidemiology of gout..  7:235-241. 2005

Update on autoantibodies in rheumatoid arthritis..  6:343-350. 2004

Ethnic disparities in patients with systemic lupus erythematosus..  5:364-369. 2003

Glucocorticoid use in rheumatoid arthritis..  4:218-225. 2002

Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations..  4:75-82. 2002

Apoptosis and rheumatoid arthritis: Past, present, and future directions.  3:70-78. 2001

Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia..  2:141-148. 2000

The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response..  1:164-171. 1999

Web alert..  1:89-90. 1999